Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 118

1.

Semisynthetic glycoconjugate based on dual role protein/PsaA as a pneumococcal vaccine.

Prasanna M, Soulard D, Camberlein E, Ruffier N, Lambert A, Trottein F, Csaba N, Grandjean C.

Eur J Pharm Sci. 2019 Mar 1;129:31-41. doi: 10.1016/j.ejps.2018.12.013. Epub 2018 Dec 17.

PMID:
30572107
2.

Alteration of Flt3-Ligand-dependent de novo generation of conventional dendritic cells during influenza infection contributes to respiratory bacterial superinfection.

Beshara R, Sencio V, Soulard D, Barthélémy A, Fontaine J, Pinteau T, Deruyter L, Ismail MB, Paget C, Sirard JC, Trottein F, Faveeuw C.

PLoS Pathog. 2018 Oct 29;14(10):e1007360. doi: 10.1371/journal.ppat.1007360. eCollection 2018 Oct.

3.

Production of Interleukin-20 cytokines limits bacterial clearance and lung inflammation during infection by Streptococcus pneumoniae.

Madouri F, Barada O, Kervoaze G, Trottein F, Pichavant M, Gosset P.

EBioMedicine. 2018 Nov;37:417-427. doi: 10.1016/j.ebiom.2018.10.031. Epub 2018 Oct 22.

4.

Natural Killer T Cells and Mucosal-Associated Invariant T Cells in Lung Infections.

Trottein F, Paget C.

Front Immunol. 2018 Aug 2;9:1750. doi: 10.3389/fimmu.2018.01750. eCollection 2018. Review.

5.

IL-17-dependent SIgA-mediated protection against nasal Bordetella pertussis infection by live attenuated BPZE1 vaccine.

Solans L, Debrie AS, Borkner L, Aguiló N, Thiriard A, Coutte L, Uranga S, Trottein F, Martín C, Mills KHG, Locht C.

Mucosal Immunol. 2018 Nov;11(6):1753-1762. doi: 10.1038/s41385-018-0073-9. Epub 2018 Aug 16.

PMID:
30115992
6.

Interleukin-22 Immunotherapy during Severe Influenza Enhances Lung Tissue Integrity and Reduces Secondary Bacterial Systemic Invasion.

Barthelemy A, Sencio V, Soulard D, Deruyter L, Faveeuw C, Le Goffic R, Trottein F.

Infect Immun. 2018 Jun 21;86(7). pii: e00706-17. doi: 10.1128/IAI.00706-17. Print 2018 Jul.

7.

CXCR1/2 Antagonism Is Protective during Influenza and Post-Influenza Pneumococcal Infection.

Tavares LP, Garcia CC, Machado MG, Queiroz-Junior CM, Barthelemy A, Trottein F, Siqueira MM, Brandolini L, Allegretti M, Machado AM, de Sousa LP, Teixeira MM.

Front Immunol. 2017 Dec 13;8:1799. doi: 10.3389/fimmu.2017.01799. eCollection 2017.

8.

Critical Role for Very-Long Chain Sphingolipids in Invariant Natural Killer T Cell Development and Homeostasis.

Saroha A, Pewzner-Jung Y, Ferreira NS, Sharma P, Jouan Y, Kelly SL, Feldmesser E, Merrill AH Jr, Trottein F, Paget C, Lang KS, Futerman AH.

Front Immunol. 2017 Nov 1;8:1386. doi: 10.3389/fimmu.2017.01386. eCollection 2017.

9.

Type I IFN Receptor Signaling Controls IL7-Dependent Accumulation and Activity of Protumoral IL17A-Producing γδT Cells in Breast Cancer.

Patin EC, Soulard D, Fleury S, Hassane M, Dombrowicz D, Faveeuw C, Trottein F, Paget C.

Cancer Res. 2018 Jan 1;78(1):195-204. doi: 10.1158/0008-5472.CAN-17-1416. Epub 2017 Oct 25.

10.

Co-delivery of the NKT agonist α-galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses.

Ghinnagow R, De Meester J, Cruz LJ, Aspord C, Corgnac S, Macho-Fernandez E, Soulard D, Fontaine J, Chaperot L, Charles J, Soncin F, Mami-Chouaib F, Plumas J, Faveeuw C, Trottein F.

Oncoimmunology. 2017 Aug 18;6(9):e1339855. doi: 10.1080/2162402X.2017.1339855. eCollection 2017.

11.

Enhancement of Adjuvant Functions of Natural Killer T Cells Using Nanovector Delivery Systems: Application in Anticancer Immune Therapy.

Ghinnagow R, Cruz LJ, Macho-Fernandez E, Faveeuw C, Trottein F.

Front Immunol. 2017 Jul 27;8:879. doi: 10.3389/fimmu.2017.00879. eCollection 2017. Review.

12.

Solubilization of α-galactosylceramide in aqueous medium: Impact on Natural Killer T cell activation and antitumor responses.

Macho-Fernandez E, Chekkat N, Ehret C, Thomann JS, De Giorgi M, Spanedda MV, Bourel-Bonnet L, Betbeder D, Heurtault B, Faveeuw C, Fournel S, Frisch B, Trottein F.

Int J Pharm. 2017 Sep 15;530(1-2):354-363. doi: 10.1016/j.ijpharm.2017.07.054. Epub 2017 Jul 22.

PMID:
28743554
13.

[Influenza and secondary bacterial infections: threats and treatments].

Roquilly A, Trottein F.

Med Sci (Paris). 2017 May;33(5):528-533. doi: 10.1051/medsci/20173305017. Epub 2017 Jun 14. Review. French.

14.

[iNKT cells: potential therapeutic targets to fight anthrax].

Le Gars M, Haustant M, Klezovich-Benard M, Paget C, Trottein F, Goossens PL, Tournier JN.

Med Sci (Paris). 2017 May;33(5):488-490. doi: 10.1051/medsci/20173305010. Epub 2017 Jun 14. French. No abstract available.

15.

Neutrophilic NLRP3 inflammasome-dependent IL-1β secretion regulates the γδT17 cell response in respiratory bacterial infections.

Hassane M, Demon D, Soulard D, Fontaine J, Keller LE, Patin EC, Porte R, Prinz I, Ryffel B, Kadioglu A, Veening JW, Sirard JC, Faveeuw C, Lamkanfi M, Trottein F, Paget C.

Mucosal Immunol. 2017 Jul;10(4):1056-1068. doi: 10.1038/mi.2016.113. Epub 2017 Jan 4.

PMID:
28051086
16.

Exogenous Activation of Invariant Natural Killer T Cells by α-Galactosylceramide Reduces Pneumococcal Outgrowth and Dissemination Postinfluenza.

Barthelemy A, Ivanov S, Hassane M, Fontaine J, Heurtault B, Frisch B, Faveeuw C, Paget C, Trottein F.

MBio. 2016 Nov 1;7(6). pii: e01440-16. doi: 10.1128/mBio.01440-16.

17.

Pseudomonas aeruginosa proteolytically alters the interleukin 22-dependent lung mucosal defense.

Guillon A, Brea D, Morello E, Tang A, Jouan Y, Ramphal R, Korkmaz B, Perez-Cruz M, Trottein F, O'Callaghan RJ, Gosset P, Si-Tahar M.

Virulence. 2017 Aug 18;8(6):810-820. doi: 10.1080/21505594.2016.1253658. Epub 2016 Oct 28.

18.

Mechanisms of Invariant NKT Cell Activity in Restraining Bacillus anthracis Systemic Dissemination.

Le Gars M, Haustant M, Klezovich-Bénard M, Paget C, Trottein F, Goossens PL, Tournier JN.

J Immunol. 2016 Oct 15;197(8):3225-3232. Epub 2016 Sep 7.

19.

Influenza A virus-induced release of interleukin-10 inhibits the anti-microbial activities of invariant natural killer T cells during invasive pneumococcal superinfection.

Barthelemy A, Ivanov S, Fontaine J, Soulard D, Bouabe H, Paget C, Faveeuw C, Trottein F.

Mucosal Immunol. 2017 Mar;10(2):460-469. doi: 10.1038/mi.2016.49. Epub 2016 May 25.

PMID:
27220813
20.

Interleukin-22 protects against non-typeable Haemophilus influenzae infection: alteration during chronic obstructive pulmonary disease.

Sharan R, Perez-Cruz M, Kervoaze G, Gosset P, Weynants V, Godfroid F, Hermand P, Trottein F, Pichavant M, Gosset P.

Mucosal Immunol. 2017 Jan;10(1):139-149. doi: 10.1038/mi.2016.40. Epub 2016 May 4.

PMID:
27143304

Supplemental Content

Loading ...
Support Center